Table 4.

Aggregated Benchmarks – DBT treatment efficacy benchmarks for adults (full-programme).

Measure	K	N	d+	σ2	CV	Q	p (Q)
	Aggregated treatment efficacy - benchmarks for RCT studies
BSL-23	2	240	0.70	0.006	–	0.02	.901
DERS	2	114	1.25	0.013	–	1.31	.253
EQ-5D-USc	4	271	0.28	0.004	–	0.92	.819
EQ-5D-VAS	4	271	0.30	0.004	–	0.16	.984
	Aggregated treatment efficacy - benchmarks for effectiveness studies
BSL-23	4	117	0.882	0.011	–	33.10	< 0.001
DERS	4	233	1.247	0.008	–	9.51	<0.050
	Treatment efficacy benchmarks for RCTs + Effectiveness
BSL-23	6	357	0.824	0.004	0.67	23.39	<0.001
DERS	6	347	1.423	0.006	81.10	24.86	<0.001
EQ-5D-USc	4	271	0.28	0.004	–	0.92	.819
EQ-5D-VAS	4	271	0.30	0.004	–	0.16	.984

Note. DBT = Dialectical Behaviour Therapy; K = number of samples included in analyses; N = sample size; d = unbiased pre–post effect size estimate; σ² = effect size variance; CV = Critical Value; Q = test of homogeneity; p = significance; BSL-23 = Borderline Symptom List; DERS = Difficulties in Emotion Regulation Scale; EQ-5D-USc: EQ-5D Utility Score; EQ-5D-VAS: EQ-5D Visual Analogue Scale.